News Headlines

  1. ERBC And Menarini Biotech Join Forces To Accelerate The Development Of Biopharmaceuticals From Research To First-In-Human Clinical Trials 4/3/2025

    ERBC, a leading preclinical contract research organization (CRO), and Menarini Biotech, a Menarini Group company, offering services as a custom development and manufacturing organization (CDMO), specialized in the development and manufacture of biopharmaceuticals, announce today a strategic partnership aimed at streamlining and speeding up the transition of biopharmaceuticals from the research stage to First- In-Human (FIH) clinical trials.

  2. Sumitomo Chemical Establishes A CRO For Oligonucleotide CDMO Business In U.S. 4/2/2025

    On April 1, 2025, Sumitomo Chemical established a new company, Sumitomo Chemical Advanced Medical Solutions America LLC (“SC-AMSA”), in Marlborough, Massachusetts, the United States. This company will serve as a CRO for Sumitomo Chemical’s Oligonucleotide CDMO2 business.

  3. AGC Biologics Launches New Dedicated Cell And Gene Business Division 4/2/2025

    While other cell and gene CDMOs are closing sites and downsizing their workforce, the new AGC Biologics Cell and Gene Technologies Division offers unparalleled support and scientific ability, backed by an abundant global development and manufacturing network in three regions (Milan, Italy; Longmont, CO, USA; Yokohama, Japan).

  4. Bend Bioscience Adds Commercial Spray Drying & Granulation In Georgia 4/2/2025

    Bend Bioscience, a leading innovation, science, and pharmaceutical services partner, today announced the addition of a commercial-scale spray dryer and a Gerteis dry granulation system at its 120,000-square-foot facility in Gainesville, Georgia.

  5. Artis BioSolutions Emerges From Stealth, Announces Acquisition Of Landmark Bio 4/2/2025

    Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, today announced its launch, alongside its acquisition of Landmark Bio.

  6. Amneal Launches BORUZU, First Ready-To-Use Bortezomib Injection For Multiple Myeloma And Mantle Cell Lymphoma 4/1/2025

    Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced the U.S. launch of BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous (IV) administration.

  7. AustinPx Launches KinetiSol Equipment Lease Program 4/1/2025

    AustinPx, a contract development and manufacturing organization (CDMO) specializing in bioavailability enhancement for orally delivered small molecule drugs, today announced the introduction of the KinetiLease program, allowing pharmaceutical companies to lease the company’s KinetiSol research-scale equipment.

  8. Lantheus Completes Acquisition Of Evergreen Theragnostics 4/1/2025

    Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. (“Evergreen”), a clinical-stage radiopharmaceutical company.

  9. Cellares' Cell Shuttle Receives FDA Advanced Manufacturing Technology (AMT) Designation For Automated Cell Therapy Manufacturing 4/1/2025

    Cellares, the first Integrated Development and Manufacturing Organization (IDMO), proudly announces that its Cell Shuttle has been granted the Advanced Manufacturing Technology (AMT) designation by the FDA’s Center for Biologics Evaluation and Research (CBER).

  10. Lonza Implements Its Simplified And Streamlined Operating Model 4/1/2025

    Lonza has announced that its new simplified and streamlined operating model is effective from today.